# Technical vs. Biological Replicates ## Quick Answer - Technical replicates measure the repeatability of your measurement process, while biological replicates capture natural variation between independent biological samples. - Use biological replicates to support claims about a population or treatment effect, and technical replicates only to confirm your assay performs consistently. - Technical replicates cannot substitute for biological replicates, and conclusions drawn from technical replicates alone overstate precision and do not generalize. ## At a Glance | Feature | Technical Replicates | Biological Replicates | | --- | --- | --- | | What is measured | Repeated measurements from the same sample or aliquot | Independent samples from separate biological entities | | Primary purpose | Assess instrument or assay precision and consistency | Capture natural biological variation and support generalization | | Example in genomics | Two sequencing runs from the same DNA library | Samples from different animals, patients, or cell culture wells | | Example in cell biology | Three counts from the same culture well | Cultures grown in separate wells or flasks from the same cell line | | Statistical role | Estimate measurement error | Estimate biological variance and treatment effects | | Can it support population claims | No | Yes | | Typical number needed | Often 2 to 3 per sample | Depends on effect size, variability, and study design | ## Defining Technical and Biological Replicates Technical replicates - defined as repeated measurements performed on the same physical aliquot - quantify assay-level measurement variability without contributing independent biological variance. Technical replicates tell you whether your measurement system is stable. If you run the same DNA library through a sequencer twice and get different results, the difference reflects instrument noise, reagent variation, or operator handling. Biological replicates tell you whether an observed effect is consistent across the natural variation present in a population. If you measure gene expression in liver tissue from five different mice and see a consistent response to a treatment, that response is more likely to reflect a real biological effect instead of a quirk of one animal. The confusion between these two types of replicates leads to a common error. Researchers sometimes treat multiple technical replicates as if they were independent observations. This inflates the apparent sample size, narrows confidence intervals, and produces p values that suggest precision the study does not actually have. The result is a conclusion that looks robust but does not generalize beyond the specific samples measured. A clear example comes from clinical trials. In the phase 3 program for upadacitinib in ulcerative colitis, the investigators ran two replicate induction studies, U-ACHIEVE and U-ACCOMPLISH, at separate clinical centers with separate patient populations. These were not repeated measurements of the same patients. They were independent trials designed to show that the treatment effect was reproducible across different groups of patients. The replicate design allowed the researchers to assess whether the observed benefit was consistent or whether it depended on the particular patients enrolled in one study. This is the logic of biological replication applied at the level of a clinical trial. See the [upadacitinib trial results on PubMed](https://pubmed.ncbi.nlm.nih.gov/35644166) for the full description of the replicate study design. The same logic applies in the bepirovirsen trials for chronic hepatitis B. Two replicate double-blind trials, B-Well 1 and B-Well 2, enrolled separate groups of patients and tested the same treatment. The functional cure rates were similar across the two trials, which strengthened the evidence that the treatment effect was real and reproducible. See the [bepirovirsen phase 3 results on PubMed](https://pubmed.ncbi.nlm.nih.gov/42206582) for details on the replicate trial structure. In the risankizumab psoriasis trials, UltIMMa-1 and UltIMMa-2 were replicate phase 3 trials conducted at different sites with different patients. The co-primary endpoints were measured in each trial separately, and the results were consistent across both. See the [risankizumab trial results on PubMed](https://pubmed.ncbi.nlm.nih.gov/30097359) for the replicate design and endpoint analysis. These examples illustrate a principle that applies to laboratory research as well. When you want to claim that a treatment works, a measurement method is reliable, or a biological process follows a pattern, you need independent replication. Technical replication alone cannot provide that evidence. ## Why the Distinction Matters for Study Validity The validity of a study depends on matching the replicate type to the question being asked. If the question is about the precision of an assay, technical replicates are appropriate. If the question is about a biological effect, biological replicates are required. Consider a gene expression experiment. You treat cells with a drug and measure mRNA levels by quantitative PCR. If you run the same cDNA sample three times on the PCR machine, you have three technical replicates. These tell you how reproducible your PCR reaction is. They do not tell you whether the drug consistently changes gene expression across different cell populations. For that, you need separate cell cultures treated with the drug, each culture representing a biological replicate. The statistical analysis must reflect this distinction. Technical replicates should be averaged to obtain a single value per biological sample. Biological replicates should be used as the unit of analysis. If you enter all technical replicates into the analysis as independent observations, you violate the assumption of independence. The analysis treats measurements from the same sample as if they came from different samples, which artificially reduces the variance and inflates the significance of the result. This error is common in genomics and cell biology. A researcher might sequence a single DNA library in duplicate, then analyze the two runs as if they represented two independent samples. The sequencing depth and coverage appear more robust than they actually are. The conclusions about differential expression or variant calling are based on a sample size of one, not two. The same problem appears in cell biology. A researcher might count cells in three fields of view from the same culture well and report the mean with a standard deviation. The standard deviation reflects variation across fields of view, not variation across independent cultures. If the experiment is repeated in another laboratory, the results may not match because the biological variation between cultures was never captured. The solution is to design experiments with biological replication from the start. The number of biological replicates needed depends on the expected effect size and the variability of the system. A pilot experiment can help estimate the variance and guide the choice of sample size. Statistical power analysis, based on the observed variance and the minimum effect of interest, provides a rational basis for the number of biological replicates. ## Technical Replicates in Genomics and Cell Biology Technical replicates serve a specific quality control function in genomics and cell biology. They detect variation introduced by the measurement process itself. This variation can come from the instrument, the reagents, the operator, or the environment. In next generation sequencing, technical replicates involve running the same library preparation through the sequencer more than once. This can be done by loading the same library on different flow cells or by running the same flow cell twice. The comparison of the two runs reveals the technical noise of the sequencing platform. If the two runs produce highly concordant results, the platform is performing consistently. If they diverge, there may be a problem with the instrument, the reagents, or the run conditions. In quantitative PCR, technical replicates are repeated reactions from the same cDNA sample. These are typically run in triplicate or quadruplicate. The cycle threshold values from the replicates are averaged, and the standard deviation provides an estimate of the assay precision. If the replicates show high variability, the assay may need optimization. The source of the variability could be pipetting error, uneven temperature distribution in the thermal cycler, or degradation of the reagents. In cell counting, technical replicates are repeated counts from the same cell suspension or the same culture well. These counts assess the consistency of the counting method. If a hemocytometer count is repeated and the numbers vary widely, the counting technique may be unreliable. The variation could come from uneven cell distribution in the counting chamber, operator counting bias, or clumping of cells. Technical replicates are also used to calibrate instruments and validate assays. A new batch of reagents can be tested by running technical replicates of a known standard. If the results fall within the expected range, the reagents are acceptable. If they do not, the batch is rejected. This quality control function is essential for maintaining consistent laboratory operations. The key limitation of technical replicates is that they cannot capture biological variation. Two sequencing runs of the same library will never reveal how different the library would be if it came from a different animal or a different cell culture. Two PCR reactions from the same cDNA will never show how much the gene expression varies between individuals. Technical replicates are a tool for quality control, not a substitute for experimental replication. ## Biological Replicates in Genomics and Cell Biology Biological replicates are independent samples that capture the natural variation in a biological system. In genomics, this means samples from different individuals, different animals, or different cell culture preparations. In cell biology, this means separate cultures, separate wells, or separate flasks that are treated identically but are not the same physical sample. The purpose of biological replicates is to support generalization. If you measure gene expression in liver tissue from five mice and all five show the same response to a treatment, you have evidence that the response is consistent across mice. If you measure the same response in five technical replicates from one mouse, you only know that the measurement is reproducible for that one mouse. The number of biological replicates required depends on the variability of the system and the size of the effect you want to detect. Systems with high biological variability require more replicates. Systems with low variability require fewer. A power analysis based on pilot data can guide this decision. In cell biology, biological replicates are often confused with technical replicates when multiple wells are treated as independent. If you seed cells into three wells from the same cell suspension and treat all three with the same drug, the wells are technical replicates of the treatment condition. They share the same cell population and the same culture history. To obtain biological replicates, you need separate cell suspensions, ideally from separate passages or separate vials of frozen cells. These independent preparations capture the variation that comes from cell culture history, passage number, and subtle differences in growth conditions. The distinction is not always absolute. In some experimental designs, wells from the same cell suspension are treated as biological replicates because the cells in each well grow independently after seeding. This is a defensible position if the wells are seeded from a common suspension but then diverge in their growth and response. However, the strongest design uses independent cell preparations for each biological replicate. In animal studies, biological replicates are individual animals. Each animal is an independent biological entity with its own genetic background, developmental history, and physiological state. The number of animals needed depends on the variability of the measured trait and the expected effect size. Animal welfare considerations require using the minimum number of animals that will provide a reliable answer, which makes power analysis especially important. ## Choosing the Right Replicate Type for Your Experiment The choice between technical and biological replicates depends on the question your experiment is designed to answer. The decision should be made during the planning phase, not after the data are collected. Start by defining the primary question. Are you asking whether your measurement method is consistent? Use technical replicates. Are you asking whether a treatment has an effect on a biological system? Use biological replicates. Are you asking whether a treatment effect is consistent across a population? Use biological replicates with enough independent samples to represent the population. Consider the following decision points: | Question | Replicate Type | Rationale | | --- | --- | --- | | Is my PCR assay reproducible? | Technical | Repeated reactions from the same cDNA reveal assay precision | | Does drug X change gene expression in liver cells? | Biological | Independent cultures treated with drug X capture biological variation | | Is the sequencing platform stable across runs? | Technical | Repeated runs of the same library reveal instrument noise | | Does drug X reduce tumor growth in mice? | Biological | Independent mice treated with drug X capture inter animal variation | | Is my cell counting method accurate? | Technical | Repeated counts of the same suspension reveal counting error | | Does the treatment effect vary across patients? | Biological | Independent patients in separate trials capture population variation | The table above shows the general pattern. Technical replicates answer questions about the measurement process. Biological replicates answer questions about the biological system. In practice, many experiments need both. A genomics experiment might use technical replicates to validate the sequencing run and biological replicates to support the biological conclusions. A cell biology experiment might use technical replicates to confirm the assay is working and biological replicates to demonstrate the treatment effect. The key is to keep the two types separate in the analysis. Technical replicates should be averaged within each biological sample. The averaged values are then analyzed across biological replicates. This two level structure is sometimes called a nested design. The technical replicates are nested within the biological replicates. ## Common Failure Patterns in Replicate Design Familiarity with common methodological pitfalls and reporting biases allows researchers to proactively design studies and analysis pipelines that are less susceptible to these systematic errors. The first failure is treating technical replicates as biological replicates. This happens when a researcher runs the same sample multiple times and then analyzes the results as if each run were an independent observation. The analysis produces narrow confidence intervals and small p values that do not reflect the true uncertainty. The conclusions are overconfident and often fail to reproduce. The second failure is using too few biological replicates. A single biological replicate, no matter how many technical replicates are measured, cannot support a general conclusion. The result may be an artifact of that particular sample. The solution is to increase the number of biological replicates, even if this means reducing the number of technical replicates per sample. The third failure is ignoring the variability between biological replicates. Some researchers report only the mean and standard deviation of technical replicates, omitting the variation between biological samples. This gives a misleading picture of the data. The variation between biological replicates is often larger than the variation between technical replicates, and it is the biologically relevant variation. The fourth failure is inconsistent handling of replicates across experiments. If one experiment uses three biological replicates and another uses five, the results are not directly comparable. The statistical power differs, and the confidence in the conclusions differs. Standardizing the number of biological replicates across related experiments improves comparability. The fifth failure is not documenting the replicate structure. If the data are recorded without indicating which measurements are technical and which are biological, the analysis cannot be done correctly. The replicate structure should be documented in the experimental records and in the data files. The sixth failure is using replicates to compensate for a poorly designed experiment. If the treatment groups are not properly randomized or the conditions are not controlled, no number of replicates will fix the problem. Replicates measure variation, they do not eliminate confounding. ## Practical Steps for Implementing Replicate Design Implementing a sound replicate design requires planning before the experiment begins. The following steps provide a practical framework. First, define the primary question and the unit of analysis. The unit of analysis is the biological sample, not the technical measurement. Write down the question in a sentence that specifies the population you want to generalize to. Second, estimate the expected variability. Use pilot data, published values, or your own experience to estimate the standard deviation of the biological measurements. If no estimate is available, run a small pilot experiment to obtain one. Third, determine the number of biological replicates needed. Use a power analysis based on the estimated variability, the minimum effect size you want to detect, and the acceptable error rates. Many free and commercial tools are available for power analysis. The analysis should be done before the experiment, not after. Fourth, decide how many technical replicates to run per biological sample. Technical replicates are useful for quality control, but they do not increase the effective sample size. Two or three technical replicates per sample are usually sufficient to confirm the assay is working. More technical replicates add little information once the assay precision is established. Fifth, plan the logistics. Biological replicates require independent samples, which may mean more animals, more cell cultures, or more patient samples. The cost and effort increase with the number of biological replicates. The power analysis helps you balance the need for precision against the practical constraints of the study. Sixth, document the replicate structure. Record which measurements are technical and which are biological. Include this information in the data files and in the methods section of any report or publication. Seventh, analyze the data correctly. Average the technical replicates within each biological sample. Use the biological replicates as the unit of analysis. Report the variation between biological replicates, beyond the variation between technical measurements. ## Records and Measurements for Replicate Tracking Accurate record keeping is essential for a valid replicate design. The records must clearly distinguish technical from biological replicates and document the conditions under which each measurement was made. For each biological replicate, record the source. In animal studies, record the animal identification number, strain, sex, age, and treatment group. In cell biology, record the cell line, passage number, culture date, and treatment conditions. In clinical research, record the patient identification number, demographics, and treatment assignment. For each technical replicate, record the sample identification and the measurement conditions. In sequencing, record the library identifier, flow cell, and run date. In PCR, record the well position, reaction plate, and run date. In cell counting, record the counting chamber, dilution factor, and operator. The records should also include any deviations from the protocol. If a sample was contaminated, a reagent was changed, or an instrument malfunctioned, this should be noted. These deviations can explain unexpected variation and should be considered in the analysis. The data files should include a column that identifies each measurement as technical or biological. This allows the analysis to be done correctly and makes the data usable by other researchers. The [NIH Data Management and Sharing Policy](https://sharing.nih.gov/data-management-and-sharing-policy) describes expectations for data sharing and management in NIH funded research. Clear documentation of the replicate structure is part of good data management. The records should be maintained in a format that is accessible and durable. Electronic laboratory notebooks, spreadsheets, and database systems are all acceptable. The key is consistency and completeness. A reviewer or collaborator should be able to understand the replicate structure from the records alone. ## Quality Controls for Replicate Experiments Quality controls are procedures that verify the experiment is working correctly. They are distinct from replicates, although they are sometimes confused with them. A positive control is a sample that is known to give a positive result. In a PCR experiment, a positive control might be a cDNA sample with a known high level of the target gene. If the positive control does not amplify, the assay has failed. A negative control is a sample that is known to give a negative result. In a PCR experiment, a negative control might be a no template reaction. If the negative control amplifies, there is contamination. Controls are not replicates. They serve a different purpose. Controls verify that the assay is working. Replicates measure variation. Both are needed for a valid experiment, but they should not be confused. Quality controls should be included in every experiment. The specific controls depend on the assay. In sequencing, controls might include a spike in of a known sequence to assess error rates. In cell culture, controls might include untreated cells to establish the baseline. In animal studies, controls might include vehicle treated animals to establish the baseline response. The results of the quality controls should be documented and reviewed before the experimental data are analyzed. If a control fails, the experiment should be repeated. Analyzing data from a failed experiment produces misleading results. The [Laboratory Biosafety Manual](https://www.who.int/publications/i/item/9789240011311) from the World Health Organization provides guidance on safe laboratory practices. While the manual focuses on biosafety, it also emphasizes the importance of standardized procedures and documentation. Consistent procedures are essential for reliable replicates. ## Statistical Analysis of Replicate Data The statistical analysis must match the replicate structure. The most common error is treating technical replicates as independent observations. This error inflates the sample size and produces invalid statistics. The correct approach is to average the technical replicates within each biological sample. This produces a single value per biological sample. The analysis is then performed on these averaged values. The number of biological replicates is the sample size for the statistical test. For example, if you have five biological replicates and three technical replicates per biological replicate, you have 15 measurements total. The correct analysis uses the five averaged values as the data. The sample size is five, not 15. The standard deviation is calculated from the five averaged values, not from the 15 individual measurements. This approach is sometimes called a nested analysis. The technical replicates are nested within the biological replicates. The variance has two components: the variance between biological replicates and the variance between technical replicates within a biological replicate. The biological variance is the relevant component for testing hypotheses about treatment effects. More sophisticated analyses can model both variance components explicitly. Mixed effects models can include biological replicates as a random effect and technical replicates as nested within them. These models provide a more complete picture of the sources of variation. However, the simple approach of averaging technical replicates first is adequate for most experiments. The statistical analysis should be planned before the experiment. The choice of test, the sample size, and the analysis method should be specified in advance. This prevents the temptation to analyze the data in multiple ways and select the result that looks best. ## Reporting Replicate Information in Publications Transparent reporting of the replicate structure is essential for the scientific record. Readers need to know how many biological replicates were used, how many technical replicates were measured, and how the data were analyzed. The EQUATOR Network curates a comprehensive, searchable catalogue of validated reporting standards - spanning clinical trials, observational studies, reviews, and qualitative research - for the full breadth of biomedical study designs. For laboratory research, the methods section should state the number of biological replicates and the number of technical replicates. The analysis should describe how the technical replicates were handled. If they were averaged, this should be stated. If a mixed effects model was used, the model should be described. The results should report the variation between biological replicates. This is the biologically relevant variation. The figures should show the individual biological replicate values, beyond the means and error bars. This allows readers to see the spread of the data. The limitations section should acknowledge any constraints on the replicate design. If the number of biological replicates was limited by cost or availability, this should be stated. If the technical replicates showed high variability, this should be noted. The [Committee on Publication Ethics Core Practices](https://publicationethics.org/core-practices) describe the responsibilities of authors, reviewers, and editors in maintaining the integrity of the scientific record. Accurate reporting of the replicate structure is part of this responsibility. Misrepresenting technical replicates as biological replicates is a form of data misrepresentation. ## Common Failure Patterns in Replicate Design Understanding where analogous analyses have historically gone wrong provides practical guidance for designing more rigorous studies and selecting more appropriate analytical methods. The first failure is treating technical replicates as biological replicates. This happens when a researcher runs the same sample multiple times and then analyzes the results as if each run were an independent observation. The analysis produces narrow confidence intervals and small p values that do not reflect the true uncertainty. The conclusions are overconfident and often fail to reproduce. The second failure is using too few biological replicates. A single biological replicate, no matter how many technical replicates are measured, cannot support a general conclusion. The result may be an artifact of that particular sample. The solution is to increase the number of biological replicates, even if this means reducing the number of technical replicates per sample. The third failure is ignoring the variability between biological replicates. Some researchers report only the mean and standard deviation of technical replicates, omitting the variation between biological samples. This gives a misleading picture of the data. The variation between biological replicates is often larger than the variation between technical replicates, and it is the biologically relevant variation. The fourth failure is inconsistent handling of replicates across experiments. If one experiment uses three biological replicates and another uses five, the results are not directly comparable. The statistical power differs, and the confidence in the conclusions differs. Standardizing the number of biological replicates across related experiments improves comparability. The fifth failure is not documenting the replicate structure. If the data are recorded without indicating which measurements are technical and which are biological, the analysis cannot be done correctly. The replicate structure should be documented in the experimental records and in the data files. The sixth failure is using replicates to compensate for a poorly designed experiment. If the treatment groups are not properly randomized or the conditions are not controlled, no number of replicates will fix the problem. Replicates measure variation, they do not eliminate confounding. ## Limitations of Replicate Design Replicate design has inherent limitations that should be acknowledged. No number of replicates can overcome fundamental flaws in the experimental design. Replicates cannot eliminate confounding. If the treatment groups differ in some way other than the treatment, the results will be confounded. For example, if all treated animals are housed in one room and all control animals in another, the room effect is confounded with the treatment effect. Replicates within each group do not solve this problem. Randomization and blocking are needed to address confounding. Replicates cannot correct for measurement bias. If the assay systematically overestimates or underestimates the true value, replicates will consistently reflect that bias. Technical replicates will show good precision but poor accuracy. The bias must be identified and corrected through calibration or comparison with a reference standard. Replicates cannot compensate for a poorly chosen model system. If the cell line or animal model does not represent the biological system of interest, the results will not generalize. Replicates within the model system will not make the results applicable to other systems. Replicates cannot overcome the limitations of the statistical analysis. If the analysis is inappropriate for the data, the conclusions will be invalid. The analysis must match the experimental design and the distribution of the data. Replicates are also limited by practical constraints. The number of biological replicates is often limited by cost, time, and ethical considerations. In animal studies, the number of animals must be minimized for welfare reasons. In clinical research, the number of patients is limited by recruitment and budget. These constraints mean that some experiments will have limited power to detect small effects. The [NIH Grants and Funding](https://grants.nih.gov/) pages describe the expectations for rigorous experimental design in NIH funded research. Grant reviewers evaluate the adequacy of the replicate design and the statistical plan. A proposal with insufficient biological replication is likely to be criticized in review. ## Safety and Regulatory Context The replicate design has implications for safety and regulatory compliance. The number of animals used in research is regulated by animal welfare laws and policies. The [NIH Grants and Funding](https://grants.nih.gov/) pages describe the requirements for humane care and use of laboratory animals. The number of animals must be justified based on the scientific objectives and the statistical design. The use of human samples and patient data is regulated by human subjects protections. The replicate design must respect the rights and welfare of the participants. The number of patients enrolled must be justified by the scientific objectives. Laboratory safety is governed by institutional policies and national guidelines. The [Laboratory Biosafety Manual](https://www.who.int/publications/i/item/9789240011311) from the World Health Organization provides guidance on safe handling of biological materials. The replicate design may require additional samples, which increases the volume of biological materials handled. The safety procedures must be followed for all samples. Data management and sharing are governed by funder policies. The [NIH Data Management and Sharing Policy](https://sharing.nih.gov/data-management-and-sharing-policy) describes the expectations for data management plans and data sharing. The replicate structure should be documented in the data management plan. Researcher identity and record keeping are supported by persistent identifiers. The [ORCID for Researchers](https://info.orcid.org/researchers) pages describe how researchers can maintain a persistent identifier that links their publications and research activities. Accurate attribution of research outputs is part of the integrity of the scientific record. ## Professional Escalation Criteria Some situations require escalation to a supervisor, a statistician, or an institutional resource. Recognizing these situations can prevent errors and improve the quality of the research. Escalate to a statistician when you are unsure about the number of biological replicates needed. A power analysis requires statistical expertise. A statistician can help you estimate the variability, choose the effect size, and determine the sample size. Escalate to a statistician when the data do not meet the assumptions of the planned analysis. If the data are not normally distributed, if the variances are unequal, or if there are outliers, the analysis may need to be adjusted. A statistician can recommend appropriate methods. Escalate to a supervisor when the results are unexpected or contradictory. An unexpected result may indicate a problem with the experiment, or it may indicate a genuine finding. A supervisor can help you interpret the result and decide on the next steps. Escalate to the institutional biosafety officer when there is a safety concern. If a sample is contaminated, if a reagent is spilled, or if there is any other safety issue, the biosafety officer should be notified. Escalate to the institutional review board or animal care committee when there is a concern about the welfare of human subjects or animals. If the experimental procedures are causing unexpected harm, the study should be paused and the oversight committee consulted. Escalate to a research integrity officer when there is a concern about data fabrication, falsification, or plagiarism. The [Committee on Publication Ethics Core Practices](https://publicationethics.org/core-practices) describe the responsibilities for handling allegations of research misconduct. Early consultation can prevent minor issues from becoming major problems. ## Frequently Asked Questions ### What is the difference between a technical replicate and a biological replicate? A technical replicate involves re-measuring the identical biological specimen under the same conditions, isolating instrumental and procedural measurement noise from true biological variation. ### How many biological replicates do I need for my experiment? The number depends on the variability of the system and the size of the effect you want to detect. A power analysis based on pilot data or published values can guide this decision. Systems with high variability require more replicates. Systems with low variability require fewer. ### Can I use technical replicates instead of biological replicates? No. Technical replicates measure the repeatability of your measurement process. They cannot capture the variation between independent biological samples. Conclusions about treatment effects or population characteristics require biological replicates. ### Why do my technical replicates show more variation than expected? High variation between technical replicates indicates a problem with the measurement process. Possible causes include pipetting error, uneven temperature distribution, reagent degradation, or instrument malfunction. The assay should be optimized and the source of the variation identified. ### Should I average technical replicates before statistical analysis? Yes. Technical replicates should be averaged within each biological sample. The averaged values are then used as the data for the statistical analysis. The number of biological replicates is the sample size, not the total number of technical measurements. ### How do I document the replicate structure in my records? Record the source of each biological sample and the conditions of each technical measurement. Include a column in your data files that identifies each measurement as technical or biological. Document any deviations from the protocol. ### What is the role of controls in a replicate experiment? Controls verify that the assay is working correctly. Positive controls confirm that the assay can detect the target. Negative controls confirm that there is no contamination. Controls are distinct from replicates and serve a different purpose. ### How do reporting guidelines help with replicate reporting? Reporting guidelines specify what information should be included in a publication to allow readers to assess the validity of the study. The [EQUATOR Network](https://www.equator-network.org/) maintains a collection of reporting guidelines for different study types. Following these guidelines improves the transparency and reproducibility of research. ## Related Diagnostic Guides - [Animal Biology](/blog/guides/animal-biology) - [Animal Research](/blog/guides/animal-research) - [Biology Facts](/blog/guides/biology-facts) ## References and Further Reading - [Research Methods Resources](https://www.ncbi.nlm.nih.gov/books). National Library of Medicine. - [EQUATOR Network](https://www.equator-network.org/). EQUATOR Network. - [Core Practices](https://publicationethics.org/core-practices). Committee on Publication Ethics. - [NIH Grants and Funding](https://grants.nih.gov/). National Institutes of Health. - [ORCID for Researchers](https://info.orcid.org/researchers). ORCID. - [Data Management and Sharing Policy](https://sharing.nih.gov/data-management-and-sharing-policy). National Institutes of Health. - [Laboratory Biosafety Manual](https://www.who.int/publications/i/item/9789240011311). World Health Organization. - [NCBI Literature Resources](https://www.ncbi.nlm.nih.gov/). National Center for Biotechnology Information. - [Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.](https://pubmed.ncbi.nlm.nih.gov/35644166). Lancet (London, England), 2022. - [Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.](https://pubmed.ncbi.nlm.nih.gov/42206582). The New England journal of medicine, 2026. - [Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.](https://pubmed.ncbi.nlm.nih.gov/30097359). Lancet (London, England), 2018. > This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.